The Effect of 8 Weeks Aerobic Exercise on LXRa, PEPCK, and G6PC2 mRNA in Obese Prediabetic Mice

Document Type : Research Paper

Authors

1 Assistant Professor of Exercise Physiology, Faculty of Human Sciences, University of Kashan, Kashan, Iran

2 Professor of Exercise Physiology, Faculty of Sport Sciences, University of Isfahan, Isfahan, Iran

3 M.Sc. of Exercise Physiology, Faculty of Sport Sciences, University of Isfahan, Isfahan, Iran

4 Professor of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

Abstract

The purpose of this study was to investigate the effect of 8 weeks aerobic exercise on the expression of LXRa, PEPCK and G6PC2 mRNA in the liver tissue of obese prediabetic mice. 18 male C57BL/6 mice were divided into two groups: 1. Mice fed a high-fat diet (prediabetic obese mice) (n=12), 2. Mice fed a standard diet (non-obese mice) (n= 6). Prediabetic conditions were confirmed by glucose tolerance test (GTT). Then, prediabetic mice were randomly divided into two groups: the high-fat diet-Exercised (HFD-Exe) and the high-fat diet-Sedentary (HFD-Sed). Exercise group were trained on a motor-driven treadmill at 21 m/min, 45 min/day, 5 days/week for 8 weeks. Mice were sacrificed 24 hours after last exercise session and blood was taken from the heart. The liver tissue was isolated and frozen to measure of LXRa and ABCA1 expression levels and was kept at -70 ̊C.Data indicated that the levels of liver LXRa and ABCA1 in trained mice were significantly higher than in untrained mice.The relative expression of key genes in gluconeogenesis, including G6PC2 and PEPCK in the liver of trained mice, was significantly reduced compared to untrained group. Also, aerobic exercise reduced steatosis and the liver enzymes in prediabetic mice.Following physical exercise, the expression of LXRa and ABCA1 mRNA expression in the liver of mice increases and protects mice from high-fat diet induced obesity and reduces the risk of NAFLD.

Keywords

Main Subjects

References

  1. Attie AD, Scherer PE. Adipocyte metabolism and obesity. Journal of Lipid Research. 2009;50(Supplement):395-9.
  2. Verma S, Hussain ME. Obesity and diabetes: an update. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;11(1):73-9.
  3. Venables MC, Jeukendrup AE. Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews. 2009;25(S1):18-23.
  4. Garber A, Handelsman Y, Einhorn D, Bergman D, Bloomgarden Z, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia—when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocrine Practice. 2008;14(7):933-46.
  5. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement 1):81-90.
  6. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/Metabolism Research and Reviews. 2006;22(6):437-43.
  7. Hoseini Kakhk SA, Khaleghzadeh H, Nematy M, Hamedinia MR. The effect of combined aerobic- resistance training on lipid profile and liver enzymes in patients with non-alcoholic fatty liver under nutrition diet. Sport Physiology. 2015;7(27):65-84. (In Persian).
  8. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50.
  9. Dixon JB, Bhathal PS, O'brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91-100.
  10. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35(4):873-8.
  11. Hajighasem A, Farzanegi P, Mazaheri Z, Naghizadeh M, Salehi G. Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver. PeerJ. 2018;6:5522.
  12. Yang G, Li C, Gong Y, Fang F, Tian H, Li J, et al. Assessment of insulin resistance in subjects with normal glucose tolerance, hyperinsulinemia with normal blood glucose tolerance, impaired glucose tolerance, and newly diagnosed type 2 diabetes (prediabetes insulin resistance research). Journal of Diabetes Research. 2016; 2016: 1-11.
  13. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovascular Diabetology. 2011;10(1):12.1-15.
  14. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proceedings of the National Academy of Sciences. 2003;100(9):5419-24.
  15. Kazeminasab F, Marandi M, Ghaedi K, Esfarjani F, Moshtaghian J. Endurance training enhances LXRα gene expression in Wistar male rats. European Journal of Applied Physiology. 2013;113(9):2285-90.
  16. Gao M, Liu D. The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance. The AAPS Journal. 2013;15(1):258-66.
  17. Chisholm JW, Hong J, Mills SA, Lawn RM. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. Journal of Lipid Research. 2003;44(11):2039-48.
  18. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. Journal of Biological Chemistry. 2003;278(2):1131-6.
  19. Efanov AM, Sewing S, Bokvist K, Gromada J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes. 2004;53(3):75-8.
  20. Bagnol D, Al‐Shamma HA, Behan D, Whelan K, Grottick AJ. Diet‐induced models of obesity (DIO) in rodents. Current Protocols in Neuroscience. 2012;59(1):1-9.
  21. Asare-Bediako B, Noothi SK, Li Calzi S, Athmanathan B, Vieira CP, Adu-Agyeiwaah Y, et al. Characterizing the Retinal Phenotype in the High-Fat Diet and Western Diet Mouse Models of Prediabetes. Cells. 2020;9(2):464. 1-18.
  22. Kazeminasab F, Marandi SM, Ghaedi K, Safaeinejad Z, Esfarjani F, Nasr-Esfahani MH. A comparative study on the effects of high-fat diet and endurance training on the PGC-1α-FNDC5/irisin pathway in obese and nonobese male C57BL/6 mice. Applied Physiology, Nutrition, and Metabolism. 2018;43(7):651-62.
  23. Powers SK, Criswell D, Lawler J, Martin D, Lieu F-K, Ji LL, et al. Rigorous exercise training increases superoxide dismutase activity in ventricular myocardium. American Journal of Physiology-Heart and Circulatory Physiology. 1993;265(6):2094-8.
  24. Kazeminasab F, Marandi SM, Ghaedi K, Esfarjani F, Nasr-Esfahani MH. The Effect of Endurance Training and High-Fat Diet on PGC-1a/FNDC5/Irisin Pathway in Male C57BL/6 Mice. Sport Physiology. 2019;11(41):63-80. (In Persian).
  25. Kim M-K, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, et al. PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. European Journal of Pharmacology. 2008;595(1-3):119-25.
  26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
  27. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology. 1999;94(9):2467-74.
  28. Sanyal AJ. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. Digestive Diseases. 2015;33(3):426-32.
  29. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, et al. Synthetic LXR agonist attenuates plaque formation in apoE-/-mice without inducing liver steatosis and hypertriglyceridemia. Journal of Lipid Research. 2009;50(2):312-26.
  30. Fernandez-Veledo S, Nieto-Vazquez I, Rondinone C, Lorenzo M. Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia. 2006;49(12):3038-48.
  31. Ebrahimi M, Fathi R, Ansari Pirsaraei Z, Talebi Garakani E. Relative Gene Expression of Key Genes Involved in Lipid Metabolism, Following High Fat Diet and Moderate and High Intensity Aerobic Training in Rat’s Liver. Sport Physiology. 2016;9(34):201-16. (In Persian).
  32. Steffensen K, Jan-Åke K. Liver X receptors: new drug targets to treat Type 2 diabetes? Future Lipidology. 2006;1(2):181-9.
  33. Kase ET, Wensaas AJ, Aas V, Højlund K, Levin K, Thoresen GH, et al. Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes. 2005;54(4):1108-15.
Sport Physiology
Volume 12, Issue 48
January 2021
Pages 17-38

Files

History

  • Receive Date: 10 April 2020
  • Revise Date: 07 July 2020
  • Accept Date: 09 August 2020

Share

How to cite

Statistics